A new classification system of anticancer drugs - Based on cell biological mechanisms

Medical Hypotheses

Volumn 66, Issue 5, 2006, Pages 883-887

  Wu, Xiong Zhi ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; AMIFOSTINE; ANGIOGENESIS INHIBITOR; ANTIBIOTIC AGENT; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; APOPTOSIS INDUCING FACTOR; AVASTINTRADE; BEVACIZUMAB; BISPHOSPHONIC ACID DERIVATIVE; CYTOSTATIC AGENT; CYTOTOXIC AGENT; DAUNORUBICIN; DIFFERENTIATION INDUCING FACTOR; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ESTRAMUSTINE; FOLINATE CALCIUM; GEFITINIB; IBRITUMOMAB TIUXETAN; IMATINIB; LIPOSOME; MESNA; MICROSPHERE; OSTEOPROTEGERIN; PLATINUM DERIVATIVE; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB; URACIL;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CHEMOPROPHYLAXIS; CHEMOSENSITIVITY; COLORECTAL CARCINOMA; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG ABSORPTION; DRUG CLASSIFICATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; HUMAN; LEUKEMIA RELAPSE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW;

EID: 32144434621     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2005.11.036     Document Type: Article

References (15)

1. E. Enrique, Z. Pilar, F. Jaime, and G.B. Manuel Classification of anticancer drugs - a new system based on therapeutic targets Cancer Treat Rev 29 2003 515 523
2. V. Krutovskikh Implication of direct host-tumor intercellular interactions in non-immune host resistance to neoplastic growth Semin Cancer Biol 12 2002 267 276
3. G. Pentheroudakis, and C. Twelves Capecitabine (Xeloda): from the laboratory to the patient's home Clin Colorectal Cancer 2 2002 16 23
4. F. Yuan, M. Dellian, and D. Fukumura Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size Cancer Res 55 1995 3752 3756
5. M.S. Cragg, C.A. Walshe, A.O. Ivanov, and M.T. Glennie The biology of CD20 and its potential as a target for mAb therapy Curr Dir Autoimmun 8 2005 140 174
6. J. Golay, L. Zaffaroni, and T. Vaccari Biologic response of B lympharma cells to antiCD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement mediated cell lysis Blood 95 2000 3900 3908
7. T.E. Witzig, I.W. Flinn, and L.I. Gordon Treatment with ibritumomab tiuxetan radioimmunotherapy inpatients with rituximab-refractory follicular non-Hodgkin's lymphoma J Clin Oncol 20 2002 3262 3269
8. D. Panda, H.P. Miller, K. Islam, and L. Wilson Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: a possible mechanistic basis for its antitumor action Proc Natl Acad Sci USA 94 1997 10560 10564
9. S. Blagden, and J. de Bono Drugging cell cycle kinases in cancer therapy Curr Drug Targets 6 2005 325 335
10. W. Zhang, M.A. Vaccariello, Y. Wang, A. Alt-Holland, N.E. Fusenig, and J.A. Garlick Escape from microenvironmental control and progression of intraepithelial neoplasia Int J Cancer 116 2005 885 893
11. E. Papp-Szabo, P.D. Josephy, and B.L. Coomber Microenvironmental influences on mutagenesis in mammary epithelial cells Int J Cancer 116 2005 679 685
12. A. Alt-Holland, W. Zhang, A. Margulis, and J.A. Garlick Microenvironmental control of premalignant disease: the role of intercellular adhesion in the progression of squamous cell carcinoma Semin Cancer Biol 15 2005 84 96
13. I. Munk Pedersen, and J. Reed Microenvironmental interactions and survival of CLL B-cells Leuk Lymphoma 45 2004 2365 2372
14. C.M. Bagi Targeting of therapeutic agents to bone to treat metastatic cancer Adv Drug Deliver Rev 57 2005 995 1010
15. D. Peer, Y. Dekel, D. Melikhov, and R. Margalit Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models Cancer Res 64 2004 7562 7569